Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Gonzalo Carreño Gomez-Tarragona"'
Autor:
Ernesto José Cuenca Zamora, Sonia Águila, María José Lis, Maria Carmen Garcia Hernandez, María Jose Fernández, María Soledad Noya Pereira, Elvira Mora Castera, Luis Palomera Bernal, Maria Alicia Senin Magan, Raúl Pérez López, Manuel Perez Encinas, Anna Angona Figueras, José Manuel Puerta, Rolando Vallansot, Venancio Conesa Garcia, Juan Carlos Hernandez-Boluda, Ana Rosell Mas, Montserrat Cortés, Guillermo Ortí, Blanca Xicoy Cirici, Gonzalo Carreño Gomez-Tarragona, Pilar Giraldo, Maria L Lozano, Valentin Garcia Gutierrez, Francisca Ferrer-Marín, On Behalf of Spanish Group of Chronic Myeloid Leukemia (Gelmc)
Publikováno v:
HemaSphere, Vol 7, p e8760624 (2023)
Externí odkaz:
https://doaj.org/article/0b343ef8d9d947e091b6ae4f23a04f80
Autor:
Inmaculada Rapado, Joaquin Martinez-Lopez, Juan Manuel de la Rosa, Ricardo Sánchez, María Linares, Yanira Heredia, José María Sánchez-Pina, Rosa Ayala, Santiago Barrio, Gonzalo Carreño Gomez-Tarragona, Jaime Carrillo, Josep-Maria Ribera, Laura Rufian, Esther Onecha, Chongwu Wang
Publikováno v:
Blood. 136:6-8
ABL1 Kinase Domain (ABL1-KD) mutations are a common resistance mechanism to tyrosine-kinase inhibitors (TKIs) in Chronic Myeloid Leukemia (CML) and Philadelphia Positive Acute Lymphoblastic Leukemia (ALL). Different ABL1-KD mutations induce different
Autor:
Alessandra Carobbio, Rosa Daffini, Tiziano Barbui, Valerio De Stefano, Marta Bellini, Alberto Marin Sanchez, Giulia Benevolo, Emma Lopez Abadia, Fabrizio Cavalca, Valentín García Gutiérrez, Daniele Cattaneo, Andrea Patriarca, Monia Marchetti, Alberto Alvarez-Larrán, Paola Guglielmelli, Steffen Koschmieder, Maria Angeles Foncillas, Marta Sobas, Blanca Xicoy, Mercedes Gasior Kabat, Alessandro Rambaldi, Estefanía Bolaños, Edyta Cichocka, Santiago Osorio, Natalia Curto-Garcia, Beatriz Cuevas, Massimiliano Bonifacio, Jean-Jacques Kiladjian, Anna Angona, Alessandro M. Vannucchi, Cristina Bucelli, Elena Magro, Laura Fox, Marcio Andrade, Francesca Palandri, Elisa Rumi, Francesca Lunghi, Begoña Navas, Martin Griesshammer, Greta Carioli, Rajko Kusec, Arianna Ghirardi, Oscar Borsani, Marco Ruggeri, Silvia Betti, Gonzalo Carreño Gomez-Tarragona, Alessandra Iurlo, Arianna Masciulli, Claire N. Harrison, Juan Carlos Hernandez Boluda, Anna Masternak, Elena Maria Elli, Miguel Sagüés, Keina Quiroz
Publikováno v:
Blood
Introduction. MPN-COVID is a European LeukemiaNet cohort study, launched in March 2020 in patients with myeloproliferative neoplasms (MPN) with COVID-19. The first cohort of 175 cases was analyzed at the end of first wave (July 2020) and results prov
Autor:
Valentín García Gutiérrez, Alberto Alvarez-Larrán, Antonia Duran, Santiago Osorio, Gonzalo Carreño Gomez-Tarragona, Joaquin Martinez-Lopez, Rafael Alonso Fernández, María Teresa Gómez-Casares, Rosa Ayala, José Morales Sánchez
Publikováno v:
Blood. 138:3655-3655
Background: Ruxolitinib is the standard of care for myelofibrosis (MF). However not all patients respond to ruxolitinib and other lose response while on treatment or require discontinuation due to adverse events. Therefore, several clinical trials wi
Autor:
Joaquin Martinez Lopez, Sandra Gomez Gomez Rojas, Fernando Calvo Boyero, Gonzalo Carreño Gomez-Tarragona, Buenaventura Buendía Ureña, Ana Jiménez, Miguel Pedrera Jimenez, Gloria Perez Segura
Publikováno v:
Blood
Introduction Hyperinflammatory response induced by the SARS-CoV19 (CV) coronavirus is the main cause of morbidity and mortality. Numerous studies have pointed-out the main role of monocyte activation. In addition neutrophils alterations appear to dif
Autor:
Noemi Alvarez, Miguel A. Sanz, Esther Onecha, María Poza, Inmaculada Rapado, Pilar Rodríguez Martínez, Juan Manuel de la Rosa, Eva Barragán, Gonzalo Carreño Gomez-Tarragona, Alba González, Joaquin Martinez-Lopez, Rosa Ayala, Rafael Colmenares, Rafael Llobet, Pau Montesinos, María Teresa Cedena
Publikováno v:
Blood. 136:41-42
Introduction: Myeloid malignancies are clonal disorders of hematopoietic stem cells and include acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN). Common biological markers have been described in the m
Autor:
María Perera, Maria Luisa Lozano, Isidro Jarque, Manuel Rodríguez López, Teresa Álvarez Roman, Silvana Novelli, María Isabel Orts, Rosa Campos, Elisa Orna, Nuria Bermejo, Maria Fernanda Lopez Fernandez, Gonzalo Carreño Gomez-Tarragona, José Ramón González-Porras, Estefanía Bolaños, Felipe Casado, Aurora de Andrés, David Valcárcel, Maria Eva Mingot-Castellano, Vicente Vicente Garcia, Tomás José González-López
Publikováno v:
Blood. 134:2361-2361
Background. Increasing age is a risk factor for vascular events but also for bleeding in immune thrombocytopenia (ITP). In elderly, meta-analysis of clinical trials of romiplostim (ROM) and eltrombopag (ELT) show that thrombopoietin receptor agonists
Autor:
Maria Eva Mingot-Castellano, Estefanía Bolaños, Nuria Bermejo, David Valcárcel, Rosa Campos, Vicente Vicente Garcia, María Perera, Silvana Novelli, Elisa Orna, Maria Fernanda Lopez Fernandez, Gonzalo Carreño Gomez-Tarragona, Tomás José González-López, Isidro Jarque, Felipe Casado, Maria Luisa Lozano, José Ramón González-Porras, María Isabel Orts, Teresa Álvarez Roman, Manuel Rodríguez López, Aurora de Andrés
Publikováno v:
Blood. 134:1088-1088
Background and aims: Significant efforts have been made in international guidelines since 2009 to establish recommendations for the initial work-up of patients with suspected immune thrombocytopenia (ITP), and to define who should be treated and how.
Autor:
Valentín García Gutiérrez, Julián Sevilla, maria Del Mar Herraez, Nuria García-Ormeña, Rosalia Riaza, Rosa Ayala, Espino Maria Jose, Francisca Ferrer Marin, José Ángel Hernández, Eva Barragán, Elena Ruiz, Vanegas Raul, Luis Felipe Casado Montero, Cristina Seri, Ricardo Sanchez, Pilar Bravo, Juan Luis Steegmann, Joaquin Martinez-Lopez, sanchez-Calero Jorge, María Monteagudo, Lucia Villalon, Eduardo Anguita, Elena Magro, Gonzalo Carreño Gomez-Tarragona, Beatriz Cuevas
Publikováno v:
Blood. 134:5368-5368
Background: Kinase domain (KD) mutations is a common resistance mechanism, secondary to the tyrosine-kinase inhibitors (ITKs) treatment in the case of chronic myeloid leukemia (CML) and Philadelphia (Ph)-positive acute lymphoblastic leukemia (ALL) pa
Autor:
Nuria Revilla, Aurora de Andrés, Maria Eva Mingot-Castellano, José Ramón González-Porras, Tomás José González-López, Maria Luisa Lozano, Maria Fernanda Lopez Fernandez, Teresa Álvarez Roman, David Valcárcel, Vicente Vicente Garcia, Nuria Bermejo, Gonzalo Carreño Gomez-Tarragona, Felipe Casado, Estefanía Bolaños, Silvana Novelli, Elisa Orna, María Perera, Isidro Jarque, María Isabel Orts, Manuel Rodríguez López, Rosa Campos
Publikováno v:
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background . In clinical practice, tapering off thrombopoietin receptor agonists (TPO-RA) in immune thrombocytopenia (ITP) is considered if therapy is no longer needed due to a decrease in the disease activity favoring sustained treatment-free respon